TRACER PHARMA ApS: Financial statements 2023
CVR: 34090106
Source: annual report 2023, Danish Business Authority
01/05/2022 – 30/04/2023
TRACER PHARMA ApS (CVR 34090106) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 4,076,390 and a net result of DKK 96,954 compared with DKK 145,040 the year before. That is an increase of 5% compared with the year before. Equity in the 2023 report amounted to DKK 1,373,959. The solvency ratio was 45.4%. The company had 5 employees in the financial year.
- Gross Profit
- DKK 4,076,390
- Profit/Loss
- DKK 96,954
- Equity
- DKK 1,373,959
- Total Assets
- DKK 3,024,931
- Employees
- 5
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 4.1 mio. | 97 t. | 1.4 mio. | 5 |
| 2022 | - | 3.9 mio. | 145 t. | 1.6 mio. | 5 |
| 2021 | - | 4 mio. | 832 t. | 1.5 mio. | 5 |
| 2020 | - | 4.4 mio. | 455 t. | 650 t. | 5 |
| 2019 | - | 3 mio. | -330 t. | 194 t. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationAbout TRACER PHARMA ApS
TRACER PHARMA ApS was a Danish company of the type Anpartsselskab based in Hørsholm, founded in 2011. The company has been dissolved on 28 November 2025. The company was registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company has 5 employees (2018). In 2025, the company reported a gross profit of DKK 5,203,816 and a net result of DKK 687,871 compared with DKK 1,705,344 the year before. Equity in the 2025 report amounted to DKK 867,174.